The success of personalized immunotherapy towards the re-activation and/or reformation of natural anti-cancer immunity may be defined by the de-activation of SphK/S1P/S1PR axis using novel inhibitors of sphingolipid pathway. This evidence concerns the gene SPHK1 and cancer.